Xagrid (anagrelide) is a prescribed medication utilized to help manage essential thrombocythemia (ET) in certain patients. This condition involves the overproduction of platelets in the bone marrow, which can elevate the risk of complications like blood clotting (thrombosis) or bleeding (hemorrhage). The primary function of this drug is to facilitate the reduction of the elevated platelet count in the bloodstream.

This medication is typically considered for patients at a heightened risk, such as those over the age of 60 or those with a previous history of clotting events. The treatment aims to ameliorate associated symptoms and help lower the probability of serious thrombotic complications that may arise from essential thrombocythemia. Xagrid is specifically indicated when patients do not tolerate or have an inadequate response to their current therapies. This therapeutic role is supported by clinical data.

Quick Fact: Relief for Elevated Platelet Counts

Regulatory References

1. European Medicines Agency therapeutic overview

Who Can and Cannot Use Xagrid?

Xagrid (anagrelide) is approved for use in adult patients with Essential Thrombocythaemia who are considered "at risk." This eligibility is typically defined by criteria such as being over 60 years of age or having a history of thrombo-haemorrhagic events. Use in the paediatric population (children and adolescents) is not recommended, as safety and efficacy have not been established in this age group.

Absolute Contraindications (Must Not Use)

Official regulatory labeling strictly prohibits the use of Xagrid in patients with:

• Known hypersensitivity to anagrelide or any of its components.
• Moderate or severe hepatic impairment (liver dysfunction).
• Moderate or severe renal impairment (kidney dysfunction, often defined as creatinine clearance less than 50 mL/min).
• Known risk factors for QT interval prolongation (a specific heart rhythm abnormality), including congenital long QT syndrome.

Restricted and Conditional Use

Caution is required for patients with any known or suspected heart disease, and treatment should proceed only after a careful assessment of risks. Patients with mild hepatic impairment also require a specific risk assessment before treatment begins. Furthermore, Xagrid is not recommended during pregnancy, and women of child-bearing potential must use adequate contraception. Breastfeeding must be discontinued during therapy.

Interactions with other medicines and products

Xagrid (anagrelide) has the potential to interact with certain medicinal products primarily due to its anti-platelet effect and its metabolic pathway involving the CYP1A2 enzyme. Careful assessment is required when combining anagrelide with other treatments.

• Other Platelet Function Modifiers: The concurrent use of anagrelide with acetylsalicylic acid (aspirin) or other medicines that inhibit or modify platelet function may increase the risk of major bleeding (haemorrhage). This combination requires caution, particularly in patients with a high bleeding risk profile.

• PDE III Inhibitors: Concomitant use with other Phosphodiesterase III (PDE III) inhibitors, such as milrinone or cilostazol, is not recommended due to the potential for exacerbation of pharmacological effects, including cardiovascular stimulation.

• CYP1A2 Enzyme Interactions: Anagrelide is metabolised mainly by the CYP1A2 liver enzyme. CYP1A2 inhibitors (e.g., fluvoxamine, enoxacin) may theoretically decrease anagrelide clearance, leading to higher exposure. Conversely, CYP1A2 inducers (e.g., omeprazole) may decrease anagrelide exposure, requiring clinical and biological monitoring. Anagrelide itself may also inhibit CYP1A2, potentially increasing the concentration of other co-administered medicines cleared by this enzyme (e.g., theophylline).

• QTc Prolongation: Anagrelide has the potential to increase the QTc interval. Caution is advised when used in patients with known risk factors for QTc prolongation or in combination with other medicinal products known to prolong the QTc interval. Close monitoring is recommended.

• Hormonal Contraceptives: Due to the potential for intestinal disturbance, anagrelide may compromise the effectiveness of hormonal oral contraceptives.

Targeted Inhibition of Platelet Production

This mechanism involves the active ingredient, Anagrelide, selectively acting on megakaryocytes—the platelet precursor cells—within the bone marrow. The drug specifically disrupts the late-stage development of these cells, a process called megakaryocytopoiesis, by intervening in the molecular sequences that guide their maturation. This targeted inhibition results in the suppression of new platelet formation, which causes a reduction in the concentration of these blood components in circulation. The final manifestation of the reduced platelet count is mechanistically constrained by the natural lifespan of existing platelets (approximately 7-10 days), meaning the cell concentration only decreases measurably after new cell production has been suppressed for a period of several days.

Secondary Mechanism: Phosphodiesterase Type 3 Modulation

Anagrelide also functions as an inhibitor of the enzyme Phosphodiesterase type 3 ( PDE3), which is prevalent in the cardiovascular system. This action causes an increase in the secondary messenger, cyclic AMP ( cAMP), in the heart muscle and blood vessel walls. The resulting physiological changes include an increase in both the force and rate of heart contraction (positive inotropy and chronotropy), and the relaxation of vascular smooth muscle, causing vasodilation. Furthermore, the precise molecular target responsible for the selective cell inhibition in the bone marrow is not fully elucidated and is understood to be a mechanism distinct from the PDE3 enzyme blockade.

Xagrid (anagrelide) is an oral hard capsule medicine. Its administration protocol is characterized by a carefully structured titration schedule and specific constraints, requiring treatment to be initiated by a clinician experienced in the management of the underlying condition. The capsules are taken with or without food but must always be swallowed whole, and instructions state they should not be crushed or diluted.

Official Administration Guidelines

Feature	Instruction
Route of Administration	Oral use only.
Adult Starting Dose	Typically 1 mg/day administered in two divided doses (0.5 mg twice daily). A starting dose of 0.5 mg four times daily is also a recognized approach.
Dose Titration Schedule	The initial dose must be maintained for at least one week. Dose adjustments must not exceed 0.5 mg/day in any one week, and the daily dose should not exceed 10 mg in total.
Population Dosing	For patients with moderate hepatic impairment, the starting dose is reduced to 0.5 mg/day. For older adults, no routine age-specific alteration in dose is required.

The usage protocol defines a long-term therapeutic regimen for the chronic condition, where the platelet count typically begins to fall within two to three weeks of treatment initiation. Platelet monitoring is required at least weekly during the dose adjustment phase until a stable maintenance dose is established. This structured, chronic use protocol, overseen by a specialist, ensures the administration is gradual and carefully controlled, adhering strictly to defined parameters.

Research Evidence / Overview of Studies for Xagrid

---

Evidence for use in Essential Thrombocythemia (ET)

Xagrid was studied for whether it was associated with reducing elevated platelet counts in people with Essential Thrombocythemia (ET), a condition characterized by fluctuating or episodic manifestations. The research examined whether the treatment was associated with a decrease in the number of platelets in the blood. Studies primarily focused on whether this decrease was observed in the patient populations included in the trials.

These early studies focused on outcomes related to systemic or functional imbalance, specifically monitoring platelet levels over defined time intervals. The findings describe patterns observed in the studies where patients had their platelet counts measured regularly. It is important to remember that these findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

---

Evidence in Patients Who Are Intolerant or Unresponsive to Other Treatments

Another area of research explored the use of Xagrid in patients with ET who had been previously treated with, or were intolerant of, other approaches. This research examined whether patterns related to reduced platelet counts were observed in this specific group.

However, the sample sizes were modest in some of these studies, and comparative evidence is lacking to fully understand the patterns observed when compared to other available approaches. The results apply only to the populations studied, and subgroup findings are uncertain due to limited patient numbers.

---

Long-term Studies and Follow-up

For managing a condition that is often long-term, research was evaluated in extended durations. Clinical research has also monitored the effects of Xagrid use over extended durations. These studies contribute to the broader evidence landscape by looking at how long the patterns observed in the studies related to reduced platelet counts were maintained and studies monitored outcomes reflecting daily functioning or activity level over time.

However, the long-term effects are not fully established, as follow-up durations were limited in some of the original clinical trials. There is limited information for long-term outcomes regarding the long-term changes observed in the condition. This means data are still emerging regarding the full effects of continuous use over many years.

---

Evidence in Special Populations

Specific research was evaluated in certain patient groups, known as special populations, including older adults and, in some cases, children. These studies examined how Xagrid was associated with platelet count changes in individuals who have other health considerations or different physiological needs than the general study population.

Data for certain groups remain insufficient to draw strong conclusions, and evidence quality varies across studies. The certainty remains low for many subgroups, such as those with pre-existing conditions (comorbidities).

---

What Is Still Uncertain About Xagrid

This section addresses areas where more research is needed and synthesizes the main limitations. Specifically, comparative evidence is lacking for many direct comparisons against other treatments. Some research reports how symptoms evolved in the observed populations, but there was observed in some studies a degree of inconsistency in the findings, meaning results were mixed across different measures. The evidence highlights what is known — and what is still uncertain, confirming that research is ongoing.

How to Store and Dispose of Xagrid

Official regulatory documents define the required conditions for storing and discarding Xagrid (anagrelide) capsules.

Storage Conditions and Stability

The medicine does not require any special storage conditions for temperature, light, or humidity. Its full shelf life is four years. However, when supplied in High-density polyethylene (HDPE) bottles, the in-use stability is limited: the contents must be used within 50 days after the bottle is first opened. The official HDPE packaging is fitted with a child-resistant closure as a mandatory safety feature.

Disposal Protocol

There are no special requirements for the product's disposal. Any unused or expired Xagrid capsules, or related waste material, must be disposed of in accordance with local requirements for medicinal products, as stipulated in official regulatory labeling.